drugset / Trial / NCT06652139
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the efficacy and safety of selinexor combined with BEAM pretreatment regimen in ASCT of recurrent and refractory DLBCL patients with immunohistochemical positive for MYC
Timeline
- Start
- 2024-11-01
- Primary completion
- 2026-11-01
- Completion
- 2028-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Background | Cytarabine | Small molecule | 200 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Melphalan | Small molecule | 140 mg/m2 | Intravenous |
| Background | carmustine | Small molecule | 300 mg/m2 | Intravenous |